全文获取类型
收费全文 | 16860篇 |
免费 | 1154篇 |
国内免费 | 72篇 |
专业分类
耳鼻咽喉 | 76篇 |
儿科学 | 365篇 |
妇产科学 | 537篇 |
基础医学 | 2831篇 |
口腔科学 | 190篇 |
临床医学 | 1694篇 |
内科学 | 3963篇 |
皮肤病学 | 145篇 |
神经病学 | 1488篇 |
特种医学 | 580篇 |
外国民族医学 | 1篇 |
外科学 | 2639篇 |
综合类 | 174篇 |
一般理论 | 7篇 |
预防医学 | 1009篇 |
眼科学 | 138篇 |
药学 | 1038篇 |
中国医学 | 21篇 |
肿瘤学 | 1190篇 |
出版年
2023年 | 56篇 |
2022年 | 100篇 |
2021年 | 233篇 |
2020年 | 142篇 |
2019年 | 259篇 |
2018年 | 335篇 |
2017年 | 209篇 |
2016年 | 269篇 |
2015年 | 358篇 |
2014年 | 482篇 |
2013年 | 691篇 |
2012年 | 1017篇 |
2011年 | 1141篇 |
2010年 | 722篇 |
2009年 | 703篇 |
2008年 | 1144篇 |
2007年 | 1155篇 |
2006年 | 1133篇 |
2005年 | 1197篇 |
2004年 | 1099篇 |
2003年 | 1079篇 |
2002年 | 1080篇 |
2001年 | 186篇 |
2000年 | 177篇 |
1999年 | 193篇 |
1998年 | 264篇 |
1997年 | 244篇 |
1996年 | 197篇 |
1995年 | 201篇 |
1994年 | 178篇 |
1993年 | 167篇 |
1992年 | 153篇 |
1991年 | 113篇 |
1990年 | 94篇 |
1989年 | 106篇 |
1988年 | 92篇 |
1987年 | 83篇 |
1986年 | 85篇 |
1985年 | 64篇 |
1984年 | 74篇 |
1983年 | 62篇 |
1982年 | 76篇 |
1981年 | 89篇 |
1980年 | 46篇 |
1979年 | 47篇 |
1978年 | 43篇 |
1977年 | 33篇 |
1976年 | 34篇 |
1975年 | 32篇 |
1973年 | 25篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
23.
24.
25.
26.
Christine Serratrice Nesma Bensalah Guillaume Penaranda Nathalie Bardin Nadia Belmatoug Agathe Masseau Christian Rose Olivier Lidove Fabrice Camou François Maillot Vanessa Leguy Nadine Magy-Bertrand Isabelle Marie Patrick Cherin Monia Bengherbia Sebastian Carballo José Boucraut Jacques Serratrice Denis Verrot 《Joint, bone, spine : revue du rhumatisme》2018,85(1):71-77
Objectives
Type 1 Gaucher disease may be related to the presence of autoantibodies. Their clinical significance is questioned.Primary endpoint was to compare the prevalence of autoantibodies in type 1 Gaucher disease patients with healthy subjects, seeking correlations with autoimmune characteristics. Secondary endpoints were to determine whether patients with autoantibodies reported autoimmunity-related symptoms and if genotype, splenectomy or treatment influenced autoantibodies presence.Methods
Type 1 Gaucher disease patients and healthy volunteers were included in this national multicenter exploratory study. Autoantibodies presence was compared in both groups and assessed regarding to genotype, splenectomy, Gaucher disease treatment and autoimmunity-related symptoms.Results
Twenty healthy subjects and 40 type 1 Gaucher disease patients were included. Of the studied group: 15 patients undergone splenectomy, 37 were treated either with enzyme replacement therapy (34) or with substrate reduction therapy (3), 25 were homozygous/heterozygous for the N370S mutation.In type 1 Gaucher disease group (studied group), 52% had positive autoantibodies versus 26% in control group. Antiphospholipid antibodies were more frequent in the studied group (30% vs. 5%), but without correlation to thrombosis, osteonecrosis or bone infarcts. In the studied group, antinuclear antibodies were more frequent (25% vs. 16%). None of the patients with autoantibodies had clinical manifestations of autoimmune diseases. Autoantibodies were not correlated with treatment, genotype, or splenectomy, except for anticardiolipid, more frequent in splenectomized patients.Conclusions
In type 1 Gaucher disease, autoantibodies were more frequent compared to a healthy population. However, they were not associated with an increased prevalence of clinical active autoimmune diseases. 相似文献27.
Kevin D. Hyde Abdullah M. S. Al-Hatmi Birgitte Andersen Teun Boekhout Walter Buzina Thomas L. DawsonJr. Dan C. Eastwood E. B. Gareth Jones Sybren de Hoog Yingqian Kang Joyce E. Longcore Eric H. C. McKenzie Jacques F. Meis Laetitia Pinson-Gadais Achala R. Rathnayaka Florence Richard-Forget Marc Stadler Bart Theelen Benjarong Thongbai Clement K. M. Tsui 《Fungal Diversity》2018,93(1):161-194
An account is provided of the world’s ten most feared fungi. Within areas of interest, we have organized the entries in the order of concern. We put four human pathogens first as this is of concern to most people. This is followed by fungi producing mycotoxins that are highly harmful for humans; Aspergillus flavus, the main producer of aflatoxins, was used as an example. Problems due to indoor air fungi may also directly affect our health and we use Stachybotrys chartarum as an example. Not everyone collects and eats edible mushrooms. However, fatalities caused by mushroom intoxications often make news headlines and therefore we include one of the most poisonous of all mushrooms, Amanita phalloides, as an example. We then move on to the fungi that damage our dwellings causing serious anxiety by rotting our timber structures and flooring. Serpula lacrymans, which causes dry rot is an excellent example. The next example serves to represent all plant and forest pathogens. Here we chose Austropuccinia psidii as it is causing devastating effects in Australia and will probably do likewise in New Zealand. Finally, we chose an important amphibian pathogen which is causing serious declines in the numbers of frogs and other amphibians worldwide. Although we target the top ten most feared fungi, numerous others are causing serious concern to human health, plant production, forestry, other animals and our factories and dwellings. By highlighting ten feared fungi as an example, we aim to promote public awareness of the cost and importance of fungi. 相似文献
28.
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo‐Controlled FREEDOM Trial and Its Extension 下载免费PDF全文
Steven R Cummings Serge Ferrari Richard Eastell Nigel Gilchrist Jens‐Erik Beck Jensen Michael McClung Christian Roux Ove Törring Ivo Valter Andrea T Wang Jacques P Brown 《Journal of bone and mineral research》2018,33(2):190-198
Denosumab reduces bone resorption and vertebral and nonvertebral fracture risk. Denosumab discontinuation increases bone turnover markers 3 months after a scheduled dose is omitted, reaching above‐baseline levels by 6 months, and decreases bone mineral density (BMD) to baseline levels by 12 months. We analyzed the risk of new or worsening vertebral fractures, especially multiple vertebral fractures, in participants who discontinued denosumab during the FREEDOM study or its Extension. Participants received ≥2 doses of denosumab or placebo Q6M, discontinued treatment, and stayed in the study ≥7 months after the last dose. Of 1001 participants who discontinued denosumab during FREEDOM or Extension, the vertebral fracture rate increased from 1.2 per 100 participant‐years during the on‐treatment period to 7.1, similar to participants who received and then discontinued placebo (n = 470; 8.5 per 100 participant‐years). Among participants with ≥1 off‐treatment vertebral fracture, the proportion with multiple (>1) was larger among those who discontinued denosumab (60.7%) than placebo (38.7%; p = 0.049), corresponding to a 3.4% and 2.2% risk of multiple vertebral fractures, respectively. The odds (95% confidence interval) of developing multiple vertebral fractures after stopping denosumab were 3.9 (2.1–7. 2) times higher in those with prior vertebral fractures, sustained before or during treatment, than those without, and 1.6 (1.3–1.9) times higher with each additional year of off‐treatment follow‐up; among participants with available off‐treatment total hip (TH) BMD measurements, the odds were 1.2 (1.1–1.3) times higher per 1% annualized TH BMD loss. The rates (per 100 participant‐years) of nonvertebral fractures during the off‐treatment period were similar (2.8, denosumab; 3.8, placebo). The vertebral fracture rate increased upon denosumab discontinuation to the level observed in untreated participants. A majority of participants who sustained a vertebral fracture after discontinuing denosumab had multiple vertebral fractures, with greatest risk in participants with a prior vertebral fracture. Therefore, patients who discontinue denosumab should rapidly transition to an alternative antiresorptive treatment. Clinicaltrails.gov : NCT00089791 (FREEDOM) and NCT00523341 (Extension). © 2017 American Society for Bone and Mineral Research. 相似文献
29.
Trevor R. Banka Allison Ruel Kara Fields Jacques YaDeau Geoffrey Westrich 《HSS journal》2015,11(1):71-75
Background
Little is known about preoperative predictors of postoperative pain and referral to a recuperative pain management service after total knee arthroplasty (TKA).Questions/Purposes
We sought to identify the preoperative predictors of postoperative pain scores, referral to a pain management service, and narcotic usage in patients undergoing primary total knee arthroplasty.Methods
We performed a prospective cohort study of 97 TKAs from a single surgeon. Pre and 6-week postoperative WOMAC, visual analog pain scale (VAS) scores, narcotic usage, and catastrophizing pain scores were collected.Results
After adjusting for all other variables, higher age and catastrophizing pain scores were associated with lower odds of postoperative opioid usage. Increasing age and BMI were associated with lower odds of being referred to pain management. There was no relationship between self-reported preoperative pain tolerance and postoperative change in WOMAC or VAS pain scores.Conclusions
This information may help surgeons advise their patients preoperatively and set expectations during the recovery period.Electronic supplementary material
The online version of this article (doi:10.1007/s11420-014-9418-4) contains supplementary material, which is available to authorized users. 相似文献30.